Fredwall, Svein O. http://orcid.org/0000-0002-2804-5783
Øverland, Britt
Berdal, Hanne
Berg, Søren
Weedon-Fekjær, Harald
Lidal, Ingeborg B.
Savarirayan, Ravi
Månum, Grethe
Funding for this research was provided by:
Dam Foundation (2019/FO249324)
The Norwegian Advisory Unit on Rare Disorders (226038)
Article History
Received: 27 October 2020
Accepted: 26 March 2021
First Online: 7 April 2021
Change Date: 18 June 2021
Change Type: Update
Change Details: The original online version of this article was revised to provide the full explanation of 'OSA' in its first appearance in the article
Declarations
:
: The study was approved by the Regional Committee for Medical and Health Research Ethics (REK) South–East, Norway (approval number 2016/2271), and is registered on ClinicalTrials.gov (NCT03780153). The study was conducted in accordance with the Helsinki Declaration for medical research, and all participants gave their informed, written consent prior to participation.
: ClinicalTrials.gov identifier NCT03780153.
: All authors have read and approved the final manuscript for publication.
: SOF has received a consulting fee from BioMarin. The authors have completed the ICMJE form and have declared no conflict of interests.